IC
SUPN icon

IEQ Capital’s Supernus Pharmaceuticals SUPN Stock Holding History

IEQ Capital’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-9,139
Closed -$437K – 2003
2025
Q3 		$437K Sell
9,139
-865
-9% -$34.8K ﹤0.01% 1366
2025
Q2 		$315K Buy
+10,004
New +$321K ﹤0.01% 1368

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

IEQ Capital's SUPN Position: Q4 2025 in Review

IEQ Capital sold out of Supernus Pharmaceuticals (SUPN) in Q4 2025, closing a stake of 9,139 shares — an estimated $437K sold.

IEQ Capital first reported a position in SUPN in Q2 2025 and held it in 2 quarters. The position peaked at $437K in Q3 2025. 333 funds tracked by Wall St. Rank hold SUPN as of Q4 2025.

  • IEQ Capital reported no remaining Supernus Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • IEQ Capital sold 9,139 Supernus Pharmaceuticals shares in Q4 2025, an estimated $437K.
  • IEQ Capital first reported a position in Supernus Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • IEQ Capital's Supernus Pharmaceuticals position peaked at $437K in Q3 2025.
  • 333 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2025.

Based on IEQ Capital's 13F filing for Q4 2025, filed 13 Feb 2026.